Upper Limb Spasticity Post-Stroke

Neurology
0
Pipeline Programs
1
Companies
1
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

1 companies ranked by most advanced pipeline stage

Ipsen
IpsenChina - Tianjin
1 program
Botulinum Toxin A Associated Costs in the Treatment of Upper Limb Spasticity Post StrokeN/A1 trial
Active Trials
NCT02384330Completed57Est. Mar 2017

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
IpsenBotulinum Toxin A Associated Costs in the Treatment of Upper Limb Spasticity Post Stroke

Clinical Trials (1)

Total enrollment: 57 patients across 1 trials

NCT02384330IpsenBotulinum Toxin A Associated Costs in the Treatment of Upper Limb Spasticity Post Stroke

Botulinum Toxin A Associated Costs in the Treatment of Upper Limb Spasticity Post Stroke

Start: Nov 2014Est. completion: Mar 201757 patients
N/ACompleted

Related Jobs in Neurology

Director, Distribution & Services

Xenon Pharmaceuticals
Remote
10h ago

Senior Medical Science Liaison (NYC Tri-State)

Xenon Pharmaceuticals
Remote
10h ago
$208K - $234K/yr

Director of Medical Affairs

CoMind
Miami, FL
10h ago

Director of Finance

CoMind
London, UK
10h ago

Electronics Engineering Manager

CoMind
London, UK
10h ago

Director of Information Technology

Zavation Medical Products
10h ago

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

1 companies competing in this space

Related Indications

Multiple Sclerosis(274)Schizophrenia(255)Epilepsy(242)Parkinson Disease(171)Alzheimer's Disease(165)Parkinson's Disease(160)Alzheimer Disease(117)Stroke(102)Relapsing-Remitting Multiple Sclerosis(83)Depression(82)